不同剂量氯沙坦对慢性心力衰竭患者血管内皮功能的影响被引量：1

导出

摘要目的:研究内皮功能不全与慢性心力衰竭的关系,并探讨不同剂量氯沙坦在心力衰竭治疗中对内皮素(ET)和一氧化氮(NO)的不同影响。方法:分别对84例慢性心力衰竭患者和28例正常对照者测定基础血浆ET值和血浆中NO值,慢性心力衰竭患者随机分成氯沙坦小剂量组与较大剂量组,治疗8周后,再次测定ET值和血NO值。结果:血浆中ET、NO含量随着心衰严重程度的加重而逐渐增高,与Boston心衰积分(BSS)呈正相关(P<0.001),与左室射血分数呈负相关(P<0.005);经抗心衰治疗后两组患者ET、NO显著降低(P<0.01),其中较大剂量组治疗后ET、NO较小剂量组明显降低(P<0.01)。结论:内皮功能损害与心力衰竭的严重程度密切相关,较大剂量的血管紧张素Ⅱ受体拮抗剂能显著降低ET、NO,更好地改善心力衰竭。

作者刘洋宋浩明邓兵赵明中

机构地区同济大学附属同济医院心血管内科

出处《实用医学杂志》 CAS 2007年第7期984-986,共3页 The Journal of Practical Medicine

关键词心力衰竭一氧化氮内皮功能不全内皮素氯沙坦

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献10

1Katz S D.Mechanisms and implications of endothelial dysfunction in congestive heart failure[J].Curt Opin Cardiol,1997,12(7):259-264.
2张晖,邓南伟,戚秀卿,罗明,邓兵.内皮功能不全在心衰中的作用[J].同济大学学报（医学版）,2001,22(4):22-25. 被引量：15
3Champion H C,Skaf M W,Hare J M.Role of nitric oxide in the pathophysiology of heart failure[J].Heart Fail Rev,2003,8(1):35-46.
4Galindo-Fraga A,Arrieta O,Castillo-Martinez L,et al.Elevation of plasmatic endothelin in patients with heart failure[J].Arch Med Res,2003,34(5):367-372.
5张传焕,鲁爱娟.氯沙坦对慢性心力衰竭患者神经内分泌的影响[J].实用医学杂志,2005,21(20):2335-2336. 被引量：2
6Sanada S,Kitakaze M,Node K,et al.Differential subcellular actions of ACE inhibitors and AT(1)receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats[J].Hypertension,2001,38(3):404-411.
7Thai H,Wollmuth J,Goldman S,et al.AT1 receptor blockade improves vasorelaxation in heart failure by up regulation of endothelial nitric oxide synthase via activation of the AT2 receptor[J].J Pharmacol Exp Ther,2003,307(3):1171-1178.
8Pitt B,Poole-Wilson P A,Segal R,et al.Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:randomised trial-the Losartan Heart Failure Survival Study ELITE Ⅱ[J].Lancet,2000,355(9215):1582-1587.
9Cohn J N,Tognoni G.A randomized trial of the angiotensin-receptor blocker valsanan in chronic heart failure[J].N Engl J Med,2001,345(23):1667-1675.
10Solomon S D,Wang D,Finn P,et al.Effect of candesartan on cause-specific mortality in heart failure patients:The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM)program[J].Circulation,2004,110(15):2180-2183.

二级参考文献8

1陈伯銮.一氧化氮的生物效应与临床的应用[J].中国急救医学,1995,15(3):50-54. 被引量：14
2Dzau VJ, Colucci WS, Hollenberg NK, et al. Relation of the renin angiotensin aldosterone system to clinical state in congestive heart failure. Circulation,1981,63(3): 645-650.
3Katz SD. The role of endothelium derived vasoactive substances in the pathphysiology of exercise intolerance in patients with congestive heart failure.Progress in Cardiovascular Diease,1995,38(5):23-50.
4Sakai S,Miyauchi T,Kobayashi M,et al.Inhibition of myocardial endothelin pathway improves long-term survival in heart failure.Nature,1996,384(7):353-355.
5Kang PM, Landau AJ, Eberhardt RT, et al, AngiotensinⅡ receptor antagonists: a new approach to blockade of the renin-angiotensin system.Am Heart J, 1994, 127(10): 1388-1401.
6Gulick J,Pieper SJ,Murphy MA, et al. A new method for assessment of culture cardiac myocyte contractility detects immune factor-mediated inhibition of beta-adrenergic respones. Circulation, 1991, 84(8):313-321.
7Pitt B,Segal R,Martinez FA,et al. Randomised trial of losartan verus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study,ELITE).Lacet,1997, 349(11): 747-752.
8Saito S,Hirata Y, Emori T, et al.AngiotensinⅡ activates endothelial constitutive nitric oxde synthase via AT1 receptor. Hypertens Res,1996,19(7):201-206.